Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic myeloid leukemia
Biotech
Terns bows out of MASH race, reverts back to phase 1
Terns Pharmaceuticals is bowing to competitive pressure and walking away from a liver disease that has long been without meaningful treatment options.
Annalee Armstrong
Jan 5, 2024 9:57am
Enliven, Imara to merge into 1 oncology biotech
Oct 14, 2022 11:30am
NexImmune cites tough competition for pausing myeloma plans
Aug 16, 2022 8:35am
Novartis' asciminib tops Pfizer's Bosulif in head-to-head trial
Dec 8, 2020 10:00am
Novartis' asciminib bests Bosulif in phase 3 leukemia trial
Aug 26, 2020 7:00am
